Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10724301
	Filing Date		2003-11-26
INFORMATION DISCLOSURE	First Named Inventor	ENEN	IKEL, Barbara
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1652
(Not for Submission under 57 51 K 1.55)	Examiner Name	Walic	ka, M.A.
	Attorney Docket Numb	er	1/1411

Examiner Cite No  1  2  If you wish to a	5179017 6060273 6063598	Kind Code <sup>1</sup> A1	1993-01 2000-05	-12	Name of Pat of cited Docu	entee or Applicant ument	Releva		Lines where	
MM 2	6060273 6063598	A1	2000-05							
Mm 3	6063598			-09	Dirks et al.					
		A1	2000 05	**						
If you wish to a		}	2000-05	-16	Enenkel et al.					
	add additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	L	Add		
		U.S.P.	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Cite Initial* No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ıment	Releva		Lines where	
1										
If you wish to a	add additional U.S. Publis	shed Ap	plication	citatio	n information p	olease click the Add	button.	Add		
•			FOREIG	N PAT	ENT DOCUM	IENTS		Remove		
Examiner Cite Initial*	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	or w	here Rele	or Relevant	T5
M 1	9208796	wo		A1	1992-05-29	Immunex Corporation	on			

Merlicker 09/20/07

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10724301
Filing Date	-	2003-11-26
First Named Inventor	ENEN	NKEL, Barbara
Art Unit		1652
Examiner Name	Walic	ka, M.A.
Attorney Docket Numb	er	1/1411

MS	2	9428143	wo	A1	1994-12-08	Targeted Genetics Corporation		
dus	3	0393438	EP	A2	1990-10-24	Boehringer Ingelheim International GMBH	·	
dw	4	9405785	wo	A1	1994-03-17	Anmelder Erfinder et al.		
del	5	9715664	wo	A1	1997-03-01	Anmelder Erfinder et al.		
MS	6	0034318	wo	A1	2000-06-15	Clontech Laboratories, Inc.		
M	7	0034326	wo	A1	2000-06-15	Clontech Laboratories, Inc.		
M	8	0034526	wo	A1	2000-06-15	Clontech Laboratories, Inc.		
M	9	0104306	wo	A1	2001-01-18	Genentech, Inc.		
dow	10	0127150	wo	A2	2001-04-19	Clontech Laboratories, Inc.		
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add button		
		<b>.</b>	NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropr date, pages(s), volume-is		<b>T</b> 5

Maliela

09/20/07

### **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number	10724301
Filing Date	2003-11-26
First Named Inventor	ENENKEL, Barbara
Art Unit	1652
Examiner Name	Walicka, M.A.
Attorney Docket Numb	per 1/1411
	<u> </u>

M	1	STEPHEN F. ALTSCHUL ET AL; Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs; Nucleic Acids Research (1997) Vol. 25 No. 17 pages 3389-3402; Oxford University Press.	
du	2	STEPHEN F. ALTSCHUL ET AL; Basic Local Alignment Search Tool; Journal of Molecular Biology (1990) Vol. 215 No. 3 pages 403-410; Academic Press Limited.	
M	3	WARREN GISH ET AL; Identification of Protein Coding Regions by Database Similarity Search; Nature Genetics (1993) Vol. 3 pages 266-272; Nature Publishing Group.	
W	4	MANFRED GOSSEN ET AL; Inducible Gene Expression Systems for Higher Eukaryotic Cells; Current Opinion in Biotechnology (1994) Vol. 5 pages 516-520; Current Biology Ltd.	
M	5	MOGENS DUCH ET AL; Determination of Transient or Stable Neo Expression Levels in Mammalian Cells; Gene (1990) Vol. 95 pages 285-288; Elsevier Science Publishers B.V.	
M	6	SHI-ZHEN HU ET AL; Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) which Exhibits Rapid, High-Level Targeting of Xenografts; Cancer Research (1996) Vol. 56 pages 3055-3061.	
M	7	JAMES S. HUSTON ET AL; Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti- Digoxin Single-Chain Fv Analogue Produced in Excherichia Coli; Proceedings of the National Academy of Sciences of the United States of America (1988) Vol. 85 pages 5879-5883.	
M	8	ALEXANDER A. KORTT ET AL; Single-Chain Fv Fragments of Anti-Neuraminidase Antibody NC10 Containing Five- and Ten-Residue Linkers Form Dimers and with Zero-Residue Linker a Trimer; Protein Engineering (1997) Vol. 10 No. 4 pages 423-433.	
M	9	BRETT LOVEJOY ET AL; crystal structure of a Synthetic Triple-Stranded Helical Bundle; Research Article (1993) Vol. 259 pages 1288-1293.	
MN	10	THOMAS L. MADDEN ET AL; Applications of Network Blast Server; Methods in Enzymology (1996) Vol. 266 pages 131-141.	
M	11	YASUMI OHSHIMA ET AL; Signals for the Selection of a Splice in Pre-mRNA Computer Analysis of Splice Junction Sequences and Like Sequences; Journal Molecular Biology (1987) Vol. 195 pages 247-259.	

Malieta 09/20/07

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10724301
Filing Date		2003-11-26
First Named Inventor	ENEN	IKEL, Barbara
Art Unit		1652
Examiner Name	Walic	ka, M.A.
Attorney Docket Numb	er	1/1411

dw	12	PETER PACK ET AL; Tetravalent Miniantibodies with High Avidity Assembling in Escherichia Coli; Journal Molecular Biology (1995) Vol. 246 pages 28-34; Academic Press Limited.	
dw	13	OLGA PERISIC ET AL; Crystal Structure of a Diabody, a Bivalent Antibody Fragment; Structure (1994) Vol. 2 pages 1217-1226; Current Biology Ltd.	
dw	14	STEVEN G. PLATT ET AL; Dot Assay for Neomycin Phosphotransferase Activity in Crude Cell Extracts; Analytical Biochemistry (1987) Vol. 162 pages 529-535; Academic Press, Inc.	
MS	15	CHRISTIAN C. SIMONSEN ET AL; Isolation and Expression of an Altered Mouse Dihydrofolate Reductase cDNA; Proceedings of the National Academy of Sciences of the United States of America (1983) Vol. 80 pages 2495-2499.	
dul	16	TEIZO YOSHIMURA ET AL; Human Monocyte Chemoattractan Protein-1 (MCP-1): Full-Length cDNA Cloning, Expression in Mitogen-Stimulated Blood Mononuclear Leukocytes, and sequence Similarity to Mouse Competence Gene JE; Febs Letters (1989) Vol. 244 No. 2 pages 487-493; Elsevier Science Publishers B.V.	
M	17	M. WIGLER ET AL; Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene; Proceedings of the National Academy of Sciences of the United States of America (1980) Vol. 77 No. 6 pages 3567-3570.	
M	18	STEFFEN FAISST ET AL; Compilation of Vertebrate-Encoded Transcription Factors; Nucleic Acids Research (1992) Vol. 20 No. 1 pages 3-26; Oxford University Press.	
UW	19	PETER PACK ET AL; Improved Bivalent Miniantibodies, with identical Avidity as whole Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli; Bio/Technology (1993) Vol. 11 pages 1271- 1277; Nature Publishing Group.	
M	20	JINGHUI ZHANG ET AL; PowerBLAST: A New Network BLAST Application for Interactive or Automated Sequence Analysis and Annotation; Genome Research (1997) Vol. 7 pages 649-656; Cold Spring Harbor Laboratory Press.	
dw	21	DANIEL A HABER ET AL; Chromosome-Mediated Transfer and Amplification of an Altered Mouse Dihydrofolate Reductase Gene; Somatic Cell Genetics (1982) Vol. 8 No. 4 pages 499-508; Plenum Publishing Corporation.	
If you wisl	n to ac	dd additional non-patent literature document citation information please click the Add button Add	

Malieles 09/20/07

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10724301
Filing Date		2003-11-26
First Named Inventor	ENEN	IKEL, Barbara
Art Unit		1652
Examiner Name	Walic	ka, M.A.
Attorney Docket Numb	er	1/1411

	EXAMINER	R SIGNATURE	
Examiner Signature	Invalidia	Date Considered	09/20/07
		tion is in conformance with MPEP 609.  of this form with next communication	
Standard ST.3). 3 For Japanese	patent documents, the indication of the year or priate symbols as indicated on the document u	P 901.04. <sup>2</sup> Enter office that issued the documen of the reign of the Emperor must precede the ser under WIPO Standard ST.16 if possible. <sup>5</sup> Applic	ial number of the patent document.

PTO/SB/08b (08-03)
Approved for use through 06/30/2008. OMB 0851-0031
U.S. Petent and Trademark Officer, U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subtest THAT PALL PLANTS for form 14498/PTO

Sheet

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

4

	Complete If Known	
Application Number	10/724,301	
Flling Date	November 26, 2003	
First Named Inventor	Barbara Enenkel	
Art Unit	To be assigned	_
Exeminer Name	To be assigned	
Attorney Docket Number	1/1411	

		NON PATENT LITERATURE COCUMENTS	
Examinar Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Barn (book, magazine, journal, sarial, symposium, catalog, etc.), date, page(e), votume-issue number(e), publisher, city and/or country where published.	۳
M		MONIQUE V. DAVIES ET AL; The Sequence Context of the Initiation Codon in the Encephalomyocarditis Virus Leader Modulates Efficiency of Internal Translation Initiation; Journal of Virology April 1992 Vol. 66 No. 4 pages 1924-1932; American Society for Microbiology	
M		D.L. BURK ET AL; Structural Analyses of Nucleotide Binding to an Aminoglycoside Phosphotransferase; Biochemistry 2001 Vol. 40 pages 8756-8764; American Chemical Society	ľ
du		ROBERT P. BENNETT ET AL; Fusion of Green Flourescent Protein with the Zeocin TM-Resistance Marker Allows Visual Screening and Drug Selection of Transfected Eukaryotic Cells; Biotechniques March, 1998 Vol. 24 No. 3 pages 478–482: Invitragen Corporation Carlebad, Ca.	
dM		MOHAMMAED A ADAM ET AL; internal initiation of Translation in Retroviral Vectors Carrying Picomavirus 5' Nontranslated Regions; Journal of Virology September 1991 Vol. 65 No. 9 pages 4985-4990; American Society for Microbiology	
W		WAI-CHING HON ET AL; Structure of an Enzyme Required for Aminoglycoside Antiblotic Resistance Reveals Homology to Eukaryotic Protein Kinases; Cell June 13,1997 Vol. 89 pages 887-895; Cell Press	
W		RICHARD L. YENGESKY ET AL: A Mutant neomycin phosphotransferese III gene reduces the resistance of transformants to antibidic selection pressure; Pro. Natl Acad. Science May 1990 Vol. 07. pages 3435-3439: Phytogen Pasadena, CA.	
W		SEMRA KOCABIYIK ET AL; Site-Specific Mutations of Conserved C-Terminal Residues in Aminoglycoside 3'-Phosphotransferase II: Phenotypic and Structural Analysis of Mutant Enzymes; Biochemical and Biophysical Research Comm. June 1992 Vol. 185 No. 3 pages 925-931; Academic	
W		J. BLAZQUEZ ET AL; Mutations in the aphA-2 gene of transposon Tn5 mapping within the regions highly conserved in aminoglycoside-phosphotransferases strongly reduce aminoglycoside resistance: Molecular Microbiology 1991 Vol. 5 No. 6 pages 1511-1518	
			<u> </u>

guoted above M 09/20/07

Examiner Signature	Malides	Date Considered	03106106

"EXAMINER: Initial if reference considered, whether or not distilen is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with east communication to applicant.

1 Applicants unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is strached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Thre will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burders, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS - ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9189 and select option 2.